{"protocolSection":{"identificationModule":{"nctId":"NCT00859014","orgStudyIdInfo":{"id":"N01-HB-37163-05"},"secondaryIdInfos":[{"id":"R21HD060978","type":"NIH","link":"https://reporter.nih.gov/quickSearch/R21HD060978"}],"organization":{"fullName":"The University of Texas Health Science Center, Houston","class":"OTHER"},"briefTitle":"Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients","officialTitle":"Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients"},"statusModule":{"statusVerifiedDate":"2014-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-01"},"primaryCompletionDateStruct":{"date":"2013-11","type":"ACTUAL"},"completionDateStruct":{"date":"2013-11","type":"ACTUAL"},"studyFirstSubmitDate":"2009-03-09","studyFirstSubmitQcDate":"2009-03-09","studyFirstPostDateStruct":{"date":"2009-03-10","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-12-18","resultsFirstSubmitQcDate":"2014-12-31","resultsFirstPostDateStruct":{"date":"2015-01-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-12-31","lastUpdatePostDateStruct":{"date":"2015-01-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Sean Savitz","investigatorTitle":"Professor, Neurology","investigatorAffiliation":"The University of Texas Health Science Center, Houston"},"leadSponsor":{"name":"The University of Texas Health Science Center, Houston","class":"OTHER"},"collaborators":[{"name":"National Institutes of Health (NIH)","class":"NIH"},{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this research study is to find out if bone marrow treatment (bone marrow aspiration and infusion of stem cells) can be safely used in adults who have recently (within 24-72 hours)suffered an acute ischemic stroke.","detailedDescription":"Our primary hypothesis is that autologous bone marrow mononuclear cell transplantation by intravenous administration is feasible and safe after acute ischemic stroke. Our secondary hypothesis is that autologous transplantation is associated with improved outcome after acute stroke."},"conditionsModule":{"conditions":["Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":25,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Autologous Bone Marrow Mononuclear Cells","type":"EXPERIMENTAL","description":"Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.","interventionNames":["Biological: Autologous Bone Marrow Mononuclear Cells"]}],"interventions":[{"type":"BIOLOGICAL","name":"Autologous Bone Marrow Mononuclear Cells","description":"Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells","armGroupLabels":["Autologous Bone Marrow Mononuclear Cells"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Study Related Serious Adverse Events (SR-SAE)","description":"Study Related Serious Adverse Events (SAE) as adjudicated by the DSMB - \"Events\"","timeFrame":"2 Years"}],"secondaryOutcomes":[{"measure":"Functional Outcome","description":"Modified Rankin Scale (mRS) Score. The mRS is a six point (scored: 0 - 5) scale that measures post stroke disability. A seventh category (mRS = 6) is for patients who have died. A higher score indicates greater degree of disability. Patients scoring '5' are bed ridden, where as those scoring '0' are completely symptom free and independent.","timeFrame":"90-days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. acute ischemic stroke\n2. age 18 to 83 years If \\>80 then the pre-stroke mRS needs to be \\< 1)\n3. Right hemisphere NIHSS 6 -15, left hemisphere NIHSS 6-18\n4. known onset time of acute symptoms\n5. stem cell transplantation procedure must be performed within 24 to 72 hrs after stroke symptom onset\n6. TPA infusion is allowed\n\nExclusion Criteria:\n\n1. NIHSS 1a \\> 1\n2. pre-stroke mRS \\> 1 if \\> 80 years of age\n3. Ischemic stroke in the last 3 months, any vascular territory\n4. MI, primary hemorrhagic or traumatic lesion of the brain within the last 3 months or identified on MRI. Small hemorrhagic transformation of the acute infarct is allowed.\n5. seizure disorder\n6. developmental delay\n7. chronic kidney disease defined as baseline creatinine \\>1.4\n8. hepatic disease or altered liver function as defined by SGPT \\>150 U/L and or T. Bilirubin \\>1.6 mg/dL at admission\n9. pulmonary disease (e.g, COPD with oxygen-requirement at rest or with ambulation, moderate to severe asthma)\n10. mechanical heart valve\n11. Active malignancy or diagnosis of malignancy within 5 years prior to the start of screening or any history of chemotherapy or radiation affecting the bone marrow. Skin cancers (except for melanoma) are permitted.\n12. prior immunosuppression, including chemotherapy administration within last 3 years or current immunosuppression as defined by WBC \\<3 x 103 cells/ml\n13. known HIV\n14. hemoglobin \\<10g/dl\n15. uncorrected coagulopathy at the time of consent defined as INR \\>1.4; PTT\\>37 sec, or thrombocytopenia (PLT\\<100,000)\n16. any hemodynamic instability at the time of consent (e.g, requiring continuous fluid resuscitation or ionotropic support).\n17. Hypoxemia (SaO2\\<90%) at the time of consent, respiratory distress or persistent hypoxemia defined as SaO2 \\<94% for \\>30 minutes occurring at any time from hospital admission to time of consent. Intubation alone is not an exclusion.\n18. pregnancy or positive b-HCG\n19. current participation in any interventional research study\n20. unable to return for follow-up visits for clinical evaluation, laboratory studies, or imaging evaluation\n21. Multiple anti-platelet medications (Aggrenox is considered a single platelet agent)\n22. Unable to undergo MRI or CT scan\n23. Any other condition that the investigator feels would pose a significant hazard to the patient if enrolled.\n24. Exclude infarct lesion size \\>145cc unless the NIHSS 1a remains \\< 1 and there is no evidence of infarct expansion or edema formation on any imaging obtained from admission up to the point just prior to infusion.\n25. Exclude IA therapy use or if there is a planned or anticipated hemicraniectomy. Diagnostic angiograms are allowed\n26. CT and/or Multimodal MRI exclusion criteria will be:\n\n    * hemispheric strokes \\< 1.5 cm maximum diameter (on the MRI as seen on the diffusion-weighted imaging or CT)\n    * midline shift \\>1mm or significant hemorrhagic transformation of the acute infarct","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"83 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Sean I Savitz, MD","affiliation":"University of Texas Heath Science Center- Houston","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Memorial Hermann Hospital-Medical Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}}]},"referencesModule":{"references":[{"pmid":"22970907","type":"BACKGROUND","citation":"Vahidy FS, Alderman S, Savitz SI. Challenges enrolling patients with acute ischemic stroke into cell therapy trials. Stem Cells Dev. 2013 Jan 1;22(1):27-30. doi: 10.1089/scd.2012.0404. Epub 2012 Oct 15."},{"pmid":"21786299","type":"RESULT","citation":"Savitz SI, Misra V, Kasam M, Juneja H, Cox CS Jr, Alderman S, Aisiku I, Kar S, Gee A, Grotta JC. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011 Jul;70(1):59-69. doi: 10.1002/ana.22458."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Autologous Bone Marrow Mononuclear Cells","description":"Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"25"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"20"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"4"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Total number of study participants","groups":[{"id":"BG000","title":"Autologous Bone Marrow Mononuclear Cells","description":"Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"25"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.7","spread":"13.3"}]}]}]},{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"13"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"12"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"14"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"11"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"25"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Study Related Serious Adverse Events (SR-SAE)","description":"Study Related Serious Adverse Events (SAE) as adjudicated by the DSMB - \"Events\"","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events","timeFrame":"2 Years","groups":[{"id":"OG000","title":"Autologous Bone Marrow Mononuclear Cells","description":"Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Functional Outcome","description":"Modified Rankin Scale (mRS) Score. The mRS is a six point (scored: 0 - 5) scale that measures post stroke disability. A seventh category (mRS = 6) is for patients who have died. A higher score indicates greater degree of disability. Patients scoring '5' are bed ridden, where as those scoring '0' are completely symptom free and independent.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"units on a scale","timeFrame":"90-days","groups":[{"id":"OG000","title":"Autologous Bone Marrow Mononuclear Cells","description":"Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","lowerLimit":"2","upperLimit":"3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"2 Years","eventGroups":[{"id":"EG000","title":"Autologous Bone Marrow Mononuclear Cells","description":"Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.","seriousNumAffected":15,"seriousNumAtRisk":25,"otherNumAffected":24,"otherNumAtRisk":25}],"seriousEvents":[{"term":"Ischemic Stroke","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Stroke Expansion","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25}]},{"term":"Syncope","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}]},{"term":"Hypotension","organSystem":"Vascular disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Renal Failure","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25}]},{"term":"Sepsis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Pulmonary Edema","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Seizure","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}]},{"term":"Carotid Hyperperfusion Syndrome","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Primary Non Small Cell Lung Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Congestive Heart Failure","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Urinary Tract Infection","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Fracture Lumbar Vertebra","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Numbness","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Hypertension","organSystem":"Vascular disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Pyelonephritis","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]},{"term":"Hospital admission for observation","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":25}]}],"otherEvents":[{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":25}]},{"term":"Leukocytopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25}]},{"term":"Pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Non-specific Musculoskeletal Pain","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":25}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}]},{"term":"Nausea","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}]},{"term":"Vomitting","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}]},{"term":"Culture Bottle Skin Contamination, Suspected","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":25}]},{"term":"Pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related. All occurred greater than 4 months after enrollment","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Nine patients were foley catheter associated. Remaining (one) experienced symptoms prior to infusion","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":25}]},{"term":"Fall","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}]},{"term":"Prolonged Partial Thromboplastin Time","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25}]},{"term":"Increased Alanine Aminotransferase","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"All events are grade 1. All patients were on statins. Three patients had transient increase within 30 days and resolved. Three patients continued to fluctuate beyond 30 days. Two patients had normal ALT up till 30 days and later had elevation","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":25}]},{"term":"Increased Aspartate Aminotransferase","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"All events are grade 1. All patients were on statins. Five patients had transient increase within 30 days and resolved. Two patients continued to fluctuate beyond 30 days. Four patients had normal AST up till 30 days and later had elevation","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":25}]},{"term":"Increased INR","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":25}]},{"term":"Increased Lipase","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Adjudicated as statin related","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}]},{"term":"Hyperglycemia","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":25}]},{"term":"Hypernatremia","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25}]},{"term":"Hypoalbuminemia","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":25}]},{"term":"Hypocalcemia","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":25}]},{"term":"Hypokalemia","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25}]},{"term":"Hyponatremia","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":25}]},{"term":"Hypophosphatemia","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25}]},{"term":"Headache","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}]},{"term":"Hemorrhagic Transformation of Ischemic Stroke","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"All events are grade 1 and were asymptomatic.","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":25}]},{"term":"Ischemic Stroke","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"All events are grade 1, were asymptomatic, and were not study related.","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":25}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":25}]},{"term":"Decubitus Ulcer","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25}]},{"term":"Peripheral Edema","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Not Study Related","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":25}]},{"term":"Hypotension","organSystem":"Vascular disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Four events were not study related. Remaining (one) was relative hypotension.","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":25}]},{"term":"Decreased Hemoglobin","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Six Not Study Related. All events grade 1 and 2","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":25}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"This is a Phase I safety and feasibility study, designed without a control group. Small sample size and inclusion of selected patients warrants caution in interpretation of findings. A randomized controlled study is needed."},"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Dr. Sean I. Savitz, Professor and Director of Stroke","organization":"University of Texas Health Science Center","email":"sean.i.savitz@uth.tmc.edu","phone":"713.500.7083"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":true}